The clinical momentum in both Alzheimer's and Parkinson's programs provides potential upside, but the narrow cash runway into Q3 2026 suggests a near-term financing need, which could lead to further dilution. Traders should monitor enrollment progress in the Phase 3 AD trial and any updates on the planned PDD study design with the FDA.
ANVS drugs
ANVS drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 16 $2.83entry
- T+1 · 8mo ago −3.18%α −3.45% · $2.74
- T+5 · 8mo ago −11.66%α −9.62% · $2.50
- T+20 · 7mo ago −38.87%α −42.65% · $1.73
- T+60 · 5mo ago −36.75%α −47.23% · $1.79
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Annovis Bio reported financial results for 2025 alongside clinical progress updates, including initiation of a pivotal Phase 3 trial in Alzheimer's disease and an open-label extension study in Parkinson's disease. The company showed improved net loss per share despite higher R&D spending, with cash of $19.5 million enabling operations into Q3 2026.
Key Financial Metrics
Key Facts
- Initiated pivotal Phase 3 trial in early Alzheimer's disease (NCT06709014) with 65% enrollment achieved by March 2026 across 83 U.S. sites.
- Launched open-label extension (OLE) study in Parkinson's disease (NCT07284784) in January 2026 to assess long-term safety and efficacy over 36 months.
- Received positive DSMB safety review for buntanetap at 6 months in the AD trial, supporting continuation without modifications.
- Met with FDA in January 2026 to discuss a potential Phase 3 trial in Parkinson's disease dementia (PDD), receiving a positive recommendation to proceed.
- Transferred patents to a new crystal form of buntanetap with improved stability, extending IP protection until 2047; 40 granted patents and 48 applications held as of year-end 2025.
- R&D expenses increased to $25.2M in 2025 from $20.0M in 2024, while G&A decreased to $4.5M from $6.7M.
- Net loss per share improved to $1.40 (basic and diluted) in 2025 vs. $2.02 (basic) and $2.31 (diluted) in 2024, despite larger total net loss due to share count increase.
- Cash and cash equivalents rose to $19.5M as of December 31, 2025, up from $10.6M in 2024; funding expected to last into Q3 2026.
Financial Impact
Net loss widened to $28.85M in 2025 from $24.59M in 2024, but per-share losses decreased due to dilution from share count rising to 27.2M. Cash position increased by $8.98M, likely from equity offerings.
Risk Factors
- Limited cash runway extending only into Q3 2026, increasing risk of near-term dilutive financing.
- No revenue-generating products; valuation dependent entirely on clinical trial outcomes.
- High market cap relative to cash and stage of development increases volatility risk if trial data disappoints.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3256164 |
Track record
19 reports on ANVS
3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +19.53% at T+20 after the May 20, 2026 report. 4 of 10 went positive at some point.
Filters
- Nov 13, 20263d ago Press Release Neutral 5/10 Entry $0.9261 Now $0.7500 −19.02% settles Feb 11
- Nov 5, 202611d ago 8-K Bearish 7/10 Entry $0.8449 Now $0.7500 +11.23% settles Feb 4
- Nov 5, 202611d ago 424B5 Bearish 7/10 Entry $0.8449 Now $0.7500 +11.23% settles Feb 4
- Nov 5, 202611d ago Press Release Bearish 7/10 Entry $0.6689 Now $0.7500 −12.12% settles Feb 3
- Nov 4, 202612d ago 424B5 Bearish 6/10 Entry $0.6689 Now $0.7500 −12.12% settles Feb 3
- Nov 4, 202612d ago Press Release Bearish 7/10 Entry $0.6689 Now $0.7500 −12.12% settles Feb 3
- Nov 4, 202612d ago 8-K Bearish 7/10 Entry $0.6689 Now $0.7500 −12.12% settles Feb 3
- Oct 30, 202617d ago 8-K Bearish 7/10 Entry $1.08 Now $0.7500 +30.56% settles Jan 29
- Oct 19, 202628d ago 8-K Neutral 1/10 Entry $0.9783 Now $0.7500 −23.34% settles Jan 15
- Oct 15, 20264w ago SC 13G/A Neutral 3/10 Entry $1.05 Now $0.7500 −28.57% settles Jan 12
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers